After more than a decade managing global biopharmaceutical portfolios, Dr. Craig Gordon, is striking out on his own with the launch of GordonMD Global Investments in Los Angeles.
GordonMD Global Investments executes investments in private and publicly traded global growth and innovative biopharmaceutical companies, with a focus on firms based in the U.S., Japan, and Europe.
With a Doctor of Medicine degree from the University of Miami Miller School of Medicine and an MBA from Duke University, Dr. Gordon is uniquely positioned at the intersection of health care and finance. He served for over 10 years as an equity investment analyst for The Capital Group, building and managing a portfolio with an average of over $7 billion in assets under management across various mandates. Prior to that he was a biotechnology equity research analyst and associate with the Cowen Group.
The amount of assets at launch of GordonMD has not been disclosed.
“At GordonMD Global Investments we employ my proprietary analysis to target truly innovative companies with best-in-class assets that move clinically with the potential not only to change the standard of care but also to generate outsized returns,” Gordon said. “The firm combines my medical and investing acumen to create a singular advantage for institutional and accredited high-net worth investors.”